tirzepatide drugs New Breakthrough Obesity Drug Tirzepatide Wins FDA Approval for

I never thought I would be able to experience that." -Krista H

SURMOUNT-1 results In this 72-week obesity trial, participants receiving tirzepatide achieved remarkable weight loss results: 5 mg dose: 85% achieved at least 5% weight reduction, with average weight loss of 15% 10 mg dose: 89% achieved at least 5% weight reduction, with average weight loss of 19% 15 mg dose: 91% achieved at least 5% weight reduction, with average weight loss of 21% These results were achieved with consistent weekly dosing

in less than three monthsand less beer and wine, as well

Certificate of Analysis Third-party verified

Who Tirzepatide Is For and Who Should Avoid It Tirzepatide is FDA-approved for specific patient groups

For many microdosers, 2.5 mg feels remarkably manageable when reached through gradual titration rather than as a starting point